-
Dr. Fei Ma: Pioneering Quality Control to Elevate Breast Cancer Care—A Comprehensive Overview of Progress and Future Directions
Breast cancer poses a significant global challenge to women’s health. In China, unprecedented efforts are being made to advance standardized diagnosis and quality control in breast cancer care. During the 2024 Conference on Standardized Diagnosis and Quality Control in Breast Cancer, Oncology Frontier interviewed the conference chair, Dr. Fei Ma from the Cancer Hospital Chinese…
-
CCHIO 2024丨Dr. Jin Zhang: Achievements of CBCS Over 38 Years and Advances in HR+ Breast Cancer Precision Diagnosis and Treatment
From November 15 to 17, 2024, the Chinese Congress on Holistic Integrative Oncology (CCHIO)(CCHIO) was held in Xi’an under the theme “Winning in Integration: Tumor Prevention and Treatment.” In the breast cancer domain, the conference integrated the latest global advancements in diagnosis, treatment, and research. At the event, Oncology Frontier interviewed Dr. Jin Zhang, Chair…
-
Dr. Qiang Wei: International and Domestic Experts Discuss Annual Advances in Urological Oncology; Demonstrating MDT Applications to Drive Standardization in China | 8th West China Uro-Oncology Tianfu Academic Conference
From November 4–10, 2024, the 8th West China Uro-Oncology Tianfu Academic Conference and the 10th Urological and Male Reproductive Oncology Annual Conference of the Sichuan Anti-Cancer Association were successfully held in Chengdu. This event shared the latest domestic and international advancements in clinical data, research findings, complex case discussions, and cutting-edge diagnostics and treatment. Following…
-
Dr. Quchang Ouyang: A New Perspective on Breast Cancer Diagnosis and Treatment—Innovative Applications of PROs in Quality Control
With advancements in breast cancer diagnosis and treatment, alongside the increasing diversity of patient needs, a comprehensive evaluation of treatment outcomes and improved quality of life have become focal points in this field. In recent years, Patient-Reported Outcomes (PROs) have emerged as a novel evaluation tool, playing an increasingly important role in breast cancer care.…
-
CCHIO 2024丨Dr. Shaoli Song: Innovative Strategies for Prostate Cancer Diagnosis and Treatment—The Increasing Value of PSMA-Targeted Therapy
Oncology Frontier: What are the characteristics of PSMA-targeted nuclear imaging techniques, and why are they widely used in prostate cancer management? Dr. Shaoli Song: Prostate-specific membrane antigen (PSMA), also known…
-
AASLD 2024丨Artificial Intelligence Enhancing Early Diagnosis of Metabolic Associated Steatotic Liver Disease
Unveiling the Diagnostic Gap Dr. Ariana Stuart, lead author and researcher from the Washington University School of Medicine, emphasized the urgency of addressing the diagnostic blind spots in MASLD management.…
-
Chinese Expertise at AASLD 2024: Dr. Huiguo Ding’s Team Advances Non-Invasive Differentiation of PSVD and Cirrhotic Portal Hypertension Using Machine
Cirrhosis is the primary cause of portal hypertension (PH), but 15-20% of PH cases stem from non-cirrhotic conditions, notably idiopathic non-cirrhotic portal hypertension (INCPH). INCPH is now categorized under the…
-
The 9th Congress of the CCIHPBA | Prof. Chaoliu Dai: Revisiting Hemorrhage Control and Residual Liver Function Protection in Hepatectomy
At the recent The 9th Congress of the Chinese Chapter of the International Hepato-Pancreato-Biliary Association (CCIHPBA), Prof. Chaoliu Dai from Shengjing Hospital of China Medical University presented on “Controlling Intraoperative Hemorrhage and Protecting Residual Liver Function in Hepatectomy.” Oncology frontier invited Prof. Dai to delve further into this topic and share insights from his presentation.
Connecting Medical Expertise through Media